Articles On Opthea (ASX:OPT)

There's something very unhealthy about the degree to which some of our pollies and journos interact with each other. They need each other, and use each other for their own purposes. The pollies to stay in power, and the journos for access a...

The S&P/ASX 200 Index (ASX: XJO) is making modest gains near midday, up 0.3% to 7,976 points. This uptick comes after a challenging session on Wednesday, which saw the index experience its worst performance in over a month. The decline...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Looking to add a few small-cap ASX healthcare stocks to your portfolio with some outsized growth potential? Considering that the small-cap sector's potential for outsized share price gains comes with added risks, we take a look at two ASX h...

ASX All Ords stock Bravura Solutions Ltd (ASX: BVS) is climbing on Wednesday after the software company posted its FY24 results. Bravura shares are currently swapping hands at $1.17 apiece, nearly 4% higher from the open. Meanwhile...

ASX All Ords stock Bravura Solutions Ltd (ASX: BVS) is climbing on Wednesday after the software company posted its FY24 results. Bravura shares are currently swapping hands at $1.17 apiece, nearly 4% higher from the open. Meanwhile...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

Bravura Solutions Ltd (ASX: BVS) shares are starting the month with a bang. In morning trade, the ASX All Ords stock is up over 7% to $1.23. Why is this ASX All Ords stock racing higher? Investors have been buying the wealth management soft...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoTech winning the race for Best in Show Aruma Resources led the small caps winners   The local benchmark moved strongly into positive terri...

If you have a high tolerance for risk and are looking for big investment returns, then read on. That's because analysts at Bell Potter have just picked out one speculative ASX stock that they believe could rise materially from current level...

The Core Lithium Ltd (ASX: CXO) share price is surging higher today. Shares in the All Ordinaries Index (ASX: XAO) lithium stock closed yesterday trading for 11 cents. In morning trade on Wednesday, shares are swapping hands for 12.5 ce...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday. In afternoon trade, the benchmark index is down 0.25% to 7,998.8 points. Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:...

It has not been an easy time to invest in ASX lithium stocks. Unless you were shorting them, lithium investors are likely to be nursing sizeable paper losses over the last 12 months. During this time, lithium stocks such as Arcadium Lithiu...

The All Ordinaries Index (ASX: XAO) is up 0.8% hitting new all-time highs, and it's getting plenty of support from this soaring ASX All Ords stock. Shares in the investment software provider closed on Friday trading for $1.07. In earlie...

The S&P/ASX 200 Index (ASX: XJO) has started the week strongly on Monday. In afternoon trade, the benchmark index is up 0.9% to 8,030.9 points. Four ASX shares that are rising more than most today are listed below. Here's why they are...

The Nanosonics Ltd (ASX: NAN) share price is having a very strong start to the week. In morning trade, the infection control specialist's shares were up as much as 10% to $3.47. Why is the Nanosonics share price surging 10%? Investors have...

It's that time of year again when investors check their leaders and laggards and potentially rotate into cheap ASX 200 stocks. Analysts have already started the process. Deterra Royalties Ltd (ASX: DRR) has caught Goldman Sachs' attentio...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

It is fair to say that the 2024 financial year was not kind to Core Lithium Ltd (ASX: CXO) shares. During the 12 months, the lithium miner's shares lost approximately 90% of their value. Will things be better for shareholders in the new fin...

Despite the past two days of solid gains, the Core Lithium Ltd (ASX: CXO) share price remains down 35.7% since this time last month. Shares in the All Ordinaries Index (ASX: XAO) lithium stock are currently flat, trading at yesterday's c...

Opthea (ASX:OPT) has announced the completion of the institutional component of the recently announced capital.

The ASX200 is down a third of a per cent to close the week. All sectors were in the red, except Consumer Discretionary stocks which pushed ahead, and, healthcare also made gains. In the Green And with the rise in Consumer Discretio...

It was another disappointing session for the Core Lithium Ltd (ASX: CXO) share price. During Friday's trade, the lithium miner's shares tumbled to a new multi-year low of 9 cents. And while it ended the day a fraction higher at 9.2 cents, t...

ASX200 dropped on Friday, extending its weekly loss despite Wall Street’s highs Telix Pharma halted US IPO; Tabcorp jumps 10pc on NSW tax reform Germany works to soften EU tariffs on Chinese electric cars   The ASX200 dropped by -0.3% on...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued finish to the week. In afternoon trade, the benchmark index is down 0.3% to 7,728.6 points. Four ASX shares that are falling more than most today are listed below. Here's why they a...

As the S&P/ASX 200 Index (ASX: XJO) slips around 0.3% into the red on Friday, one ASX 200 stock has copped a hammering. Deterra Royalties Ltd (ASX: DRR) shares took a significant hit at the open and were down 10% in early trade. Howe...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Australian company Opthea (ASX:OPT) has announced it is seeking to raise approximately $227.3 million to advance the late-stage development of OPT-302 (sozinibercept), a drug for progressive retinal diseases, including wet age-relat...

ASX down 0.5pc, Energy sector up due mainly to Woodside’s upgrade. CRH to acquire Adbri, ending Adbri’s 62-year ASX presence China’s data CPI keeps increasing, new data shows   The ASX continued yesterday’s decline, down another -0.5% tod...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

PainChek granted patent in Europe PainChek (ASX:PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent was given for the PainChek app, an AI platform designed to analyse facial expressions, voc...

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Cheap ASX shares are capable of paying very high dividend yields because of their cheap valuation. Assuming a dividend cut isn't coming, a big potential yield can be very appealing because of how much it can contribute to total sharehold...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

A2 Milk Company Ltd (ASX: A2M) shares are on form and rising nicely on Tuesday. At the time of writing, the infant formula company's shares are up almost 2% to $5.86. Why are A2 Milk shares rising? Investors may have been buying the company...

Much to the relief of Aussie investors, the S&P/ASX 200 Index (ASX: XJO) is having a much better session on Thursday. In afternoon trade, the benchmark index is up 0.5% to 7,819.2 points. Four ASX shares that have failed to follow the...

“It’s a privilege to join the Board of Opthea at such a transformative time,” said Sujal Shah. “I look forward to partnering with the executive leadership team and the Board as we continue to drive sozinibercept forward, with the go...

Opthea look to transform standard of care treatment for wet AMD to improve vision outcomes Two Phase 3 trials are underway investigating lead drug OPT-302 with results from both forecast mid 2025 Opthea looking to be first drug statistical...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Clarity says initial data from Phase 1/2 trial is positive Opthea completes enrolment of all patients in the COAST Phase 3 trial ProMedicus locks in record half   Clarity’s Phase 1/2 trial shows positive initial results Clarity Pharmaceut...

Opthea (ASX:OPT) has announced that it has completed the enrolment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept in combination with aflibercept.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Opthea (ASX:OPT) has announced that CEO Dr Megan Baldwin will transition to founder and chief innovation officer, appointing US-based executives Dr Frederic Guerard as CEO and Peter Lang as chief financial officer.

Benchmark ASX index closes short by -0.04% Materials sector tries but cannot offset everyone else  Small caps led by HAL, DTC   The ASX200 Index has closed slightly lower after jumping early (+0.3%) out the gates on Wednesday morning. The...

Broker Rating Changes (PostThursday Last Week) Upgrade AMA GROUP LIMITED ((AMA)) Upgrade to Buy from Speculative Buy by Canaccord Genuity.B/H/S: 0/0/0 Having recently completed a $55m capital raise,AMA Group is set to deploy $35mto repay se...